European Commission Approves Pfizer's DURVEQTIX, A One-Time Gene Therapy For Adults With Hemophilia B
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted conditional marketing authorization to Pfizer's DURVEQTIX, a one-time gene therapy for adults with hemophilia B. This therapy has shown significant efficacy in reducing bleeds and could replace the need for regular prophylaxis treatments.
July 25, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's DURVEQTIX has received conditional marketing authorization from the European Commission for the treatment of hemophilia B. This approval could significantly impact Pfizer's revenue and market position in the gene therapy space.
The approval of DURVEQTIX by the European Commission is a significant milestone for Pfizer, potentially leading to increased revenue and market share in the gene therapy sector. The therapy's efficacy in reducing bleeds and the convenience of a one-time dose make it a compelling alternative to current treatments.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100